Kees Spruijt

About

Kees Spruijt is a leading researcher in radiation oncology, specializing in stereotactic body radiotherapy (SBRT) and advanced treatment planning for both pulmonary and ocular cancers. His major contributions include pioneering dose prescription methodologies that enhance interinstitutional consistency in lung SBRT, notably through the use of mean internal target volume dose to harmonize outcomes across diverse technologies. With 11 citations, his 2021 work on pulmonary SBRT standardization has provided a critical framework for improving treatment reproducibility and efficacy. More recently, Spruijt has advanced the field with an artificial intelligence-based clinical decision-making tool for uveal melanoma, enabling rapid prediction of dosimetric outcomes to streamline the choice between stereotactic radiation therapy and proton therapy. This innovative work, published in 2025, demonstrates his commitment to integrating AI into personalized radiotherapy planning. Spruijt’s research bridges technical precision and clinical applicability, offering practical solutions that reduce variability and enhance decision-making in radiation oncology. His achievements underscore a career dedicated to improving treatment consistency and patient outcomes through cutting-edge dosimetric and AI-driven approaches.

Research Focus

Key Achievements

Top Papers

1. 1
   Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose

   11 citations · 2021
2. 2
   Stereotactic Radiation Therapy or Protons for Uveal Melanoma Patients? An Artificial Intelligence (AI)-Based Clinical Treatment Decision-Making Tool Predicting Doses To Radiation Therapy Constraints

   2 citations · 2025

Key Collaborators

Contact & Links